148 related articles for article (PubMed ID: 29278452)
1. Sulfonylurea vs insulin therapy in individuals with sulfonylurea-sensitive permanent neonatal diabetes mellitus, attributable to a KCNJ11 mutation, and poor glycaemic control.
Stanik J; Dankovcikova A; Barak L; Skopkova M; Palko M; Divinec J; Klimes I; Gasperikova D
Diabet Med; 2018 Mar; 35(3):386-391. PubMed ID: 29278452
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
Bowman P; Sulen Å; Barbetti F; Beltrand J; Svalastoga P; Codner E; Tessmann EH; Juliusson PB; Skrivarhaug T; Pearson ER; Flanagan SE; Babiker T; Thomas NJ; Shepherd MH; Ellard S; Klimes I; Szopa M; Polak M; Iafusco D; Hattersley AT; Njølstad PR;
Lancet Diabetes Endocrinol; 2018 Aug; 6(8):637-646. PubMed ID: 29880308
[TBL] [Abstract][Full Text] [Related]
3. Unsuccessful switch from insulin to sulfonylurea therapy in permanent neonatal diabetes mellitus due to an R201H mutation in the KCNJ11 gene: a case report.
Heo JW; Kim SW; Cho EH
Diabetes Res Clin Pract; 2013 Apr; 100(1):e1-2. PubMed ID: 23434183
[TBL] [Abstract][Full Text] [Related]
4. First case of neonatal diabetes with KCNJ11 Q52R mutation successfully switched from insulin to sulphonylurea treatment.
Ioacara S; Flanagan S; Fröhlich-Reiterer E; Goland R; Fica S
J Diabetes Investig; 2017 Sep; 8(5):716-719. PubMed ID: 28083968
[TBL] [Abstract][Full Text] [Related]
5. Familial permanent neonatal diabetes with KCNJ11 mutation and the response to glyburide therapy--a three-year follow-up.
Begum-Hasan J; Polychronakos C; Brill H
J Pediatr Endocrinol Metab; 2008 Sep; 21(9):895-903. PubMed ID: 18924582
[TBL] [Abstract][Full Text] [Related]
6. Comparison of diabetes phenotype in children and their mothers with permanent neonatal diabetes mellitus carrying the same
Stanik J; Barak L; Dankovcikova A; Valkovicova T; Skopkova M; Gasperikova D
Endocr Regul; 2020 Nov; 54(4):260-265. PubMed ID: 33885251
[No Abstract] [Full Text] [Related]
7. Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.
Lau E; Correia C; Freitas P; Nogueira C; Costa M; Saavedra A; Costa C; Carvalho D; Fontoura M
Arch Endocrinol Metab; 2015 Dec; 59(6):559-61. PubMed ID: 26331221
[TBL] [Abstract][Full Text] [Related]
8. Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encoding Kir6.2.
Kim MS; Kim SY; Kim GH; Yoo HW; Lee DW; Lee DY
J Korean Med Sci; 2007 Aug; 22(4):616-20. PubMed ID: 17728498
[TBL] [Abstract][Full Text] [Related]
9. Personalized medicine switching from insulin to sulfonylurea in permanent neonatal diabetes mellitus dictated by a novel activating ABCC8 mutation.
Mak CM; Lee CY; Lam CW; Siu WK; Hung VC; Chan AY
Diagn Mol Pathol; 2012 Mar; 21(1):56-9. PubMed ID: 22306677
[TBL] [Abstract][Full Text] [Related]
10. Successful transition from insulin to sulfonylurea therapy in a patient with monogenic neonatal diabetes owing to a KCNJ11 F333L [corrected] mutation.
Philla KQ; Bauer AJ; Vogt KS; Greeley SA
Diabetes Care; 2013 Dec; 36(12):e201. PubMed ID: 24265373
[No Abstract] [Full Text] [Related]
11. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.
Babiker T; Vedovato N; Patel K; Thomas N; Finn R; Männikkö R; Chakera AJ; Flanagan SE; Shepherd MH; Ellard S; Ashcroft FM; Hattersley AT
Diabetologia; 2016 Jun; 59(6):1162-6. PubMed ID: 27033559
[TBL] [Abstract][Full Text] [Related]
12. Permanent neonatal diabetes mellitus due to KCNJ11 mutation in a Portuguese family: transition from insulin to oral sulfonylureas.
Dupont J; Pereira C; Medeira A; Duarte R; Ellard S; Sampaio L
J Pediatr Endocrinol Metab; 2012; 25(3-4):367-70. PubMed ID: 22768671
[TBL] [Abstract][Full Text] [Related]
13. Sulfonylurea treatment in a girl with neonatal diabetes (KCNJ11 R201H) and celiac disease: impact of low compliance to the gluten free diet.
Delvecchio M; Zecchino C; Faienza MF; Acquafredda A; Barbetti F; Cavallo L
Diabetes Res Clin Pract; 2009 Jun; 84(3):332-4. PubMed ID: 19345438
[TBL] [Abstract][Full Text] [Related]
14. Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes.
Thurber BW; Carmody D; Tadie EC; Pastore AN; Dickens JT; Wroblewski KE; Naylor RN; Philipson LH; Greeley SA;
Diabetologia; 2015 Jul; 58(7):1430-5. PubMed ID: 25877689
[TBL] [Abstract][Full Text] [Related]
15. Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide.
Bremer AA; Ranadive S; Lustig RH
Pediatr Diabetes; 2008 Jun; 9(3 Pt 1):236-9. PubMed ID: 18221420
[TBL] [Abstract][Full Text] [Related]
16. Improved long-term glucose control in neonatal diabetes mellitus after early sulfonylurea allergy.
Shah B; Breidbart E; Pawelczak M; Lam L; Kessler M; Franklin B
J Pediatr Endocrinol Metab; 2012; 25(3-4):353-6. PubMed ID: 22768668
[TBL] [Abstract][Full Text] [Related]
17. Successful sulfonylurea treatment of an insulin-naïve neonate with diabetes mellitus due to a KCNJ11 mutation.
Wambach JA; Marshall BA; Koster JC; White NH; Nichols CG
Pediatr Diabetes; 2010 Jun; 11(4):286-8. PubMed ID: 19656320
[TBL] [Abstract][Full Text] [Related]
18. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.
Slingerland AS; Nuboer R; Hadders-Algra M; Hattersley AT; Bruining GJ
Diabetologia; 2006 Nov; 49(11):2559-63. PubMed ID: 17047922
[TBL] [Abstract][Full Text] [Related]
19. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Pearson ER; Flechtner I; Njølstad PR; Malecki MT; Flanagan SE; Larkin B; Ashcroft FM; Klimes I; Codner E; Iotova V; Slingerland AS; Shield J; Robert JJ; Holst JJ; Clark PM; Ellard S; Søvik O; Polak M; Hattersley AT;
N Engl J Med; 2006 Aug; 355(5):467-77. PubMed ID: 16885550
[TBL] [Abstract][Full Text] [Related]
20. Molecular Genetics, Clinical Characteristics, and Treatment Outcomes of K
Ngoc CTB; Dien TM; De Franco E; Ellard S; Houghton JAL; Lan NN; Thao BP; Khanh NN; Flanagan SE; Craig ME; Dung VC
Front Endocrinol (Lausanne); 2021; 12():727083. PubMed ID: 34566892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
